Itonis, Inc. announces selection of new manufacturer for Emesyl
anti-nausea relief
LAGUNA HILLS, CA (March 28, 2016) - Itonis, Inc. (OTC
PINKSHEETS: ITNS)
Itonis, Inc. is pleased to announce that National Homeopathic
Labs will be the new manufacturer for its anti-nausea product,
Emesyl. National Homeopathic Labs is a cGMP, FDA registered
contract manufacturer that has specialized in formula development
and packaging of homeopathic, nutritional, cosmeceutal, and dietary
supplements for over 25 years.
Itonis has placed its first purchase order with National
Homeopathic Labs and is expecting delivery of its first batch of
product within the next 2 months.
We are very pleased to be working with National Homeopathic Labs
and look forward to a long standing relationship with them said
Steve Pidliskey, Itonis Vice President. Once they delivered the
first batch of samples to us and we had time to test them, we
immediately knew we had a sure winner.
About Itonis, Inc.
Located in Laguna Hills, California, and founded in 2005, Itonis
Inc. has focused on the distribution of innovative products to the
medical and pharmaceutical industries. The company also holds a
licensing agreement with MyECheck Inc, which allows the company to
use MyEChecks patented mobile payment application and share
transaction revenue fees for point of purchase payments across
various industries. Please visit www.itonisholdings.com for additional information.
About National Homeopathic Labs.
Located in Las Vegas, Nevada, the company is a cGMP, FDA
registered contract manufacturer that specializes in formula
development and packaging of homeopathic, nutritional, cosmeceutal,
and dietary supplements.
Safe Harbor:
Statements in this press release may constitute forward-looking
statements and are subject to numerous risks and uncertainties,
including the failure to complete successfully the development of
new or enhanced products, the Company's future capital needs, the
lack of market demand for any new or enhanced products the Company
may develop, any actions by the Company's affiliates that may be
adverse to the Company, the success of competitive products, other
economic factors affecting the Company and its markets, seasonal
changes, and other risks detailed from time to time in the
Company's filings with the U.S. Securities and Exchange Commission.
The actual results may differ materially from those contained in
this press release. The Company disclaims any obligation to update
any statements in this press release.
Contact:
Itonis, Inc.
Office@itonisholdings.com